A brief overview of the key points discussed during a company’s quarterly earnings call, including financial performance, guidance, and management’s commentary on future outlook.
Biocytogen Pharmaceuticals (Beijing) Earnings
Estimates
Actual
Y-on-Y Change
Revenue
EPS
Transcripts
Events
About Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
B
B
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
2315
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors. In addition, its preclinical candidates include YH012 and YH013, fully human anti-HER2/TROP2 bispecific antibody drugs conjugate for therapeutic product development, manufacturing, and commercialization for all human indications; YH015, a fully human IgG1 antagonistic monoclonal antibody targeting CD40; and YH016 and YH017, two novel molecules. The company has collaboration with Syncromune, Inc.; out license agreement with RemeGen Co., Ltd.; and license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was incorporated in 2009 and is headquartered in Beijing, China.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized ant...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors. In addition, its preclinical candidates include YH012 and YH013, fully human anti-HER2/TROP2 bispecific antibody drugs conjugate for therapeutic product development, manufacturing, and commercialization for all human indications; YH015, a fully human IgG1 antagonistic monoclonal antibody targeting CD40; and YH016 and YH017, two novel molecules. The company has collaboration with Syncromune, Inc.; out license agreement with RemeGen Co., Ltd.; and license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was incorporated in 2009 and is headquartered in Beijing, China.
Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach. Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
